Brief: 89bio Receives EMA PRIME Status For Pegozafermin In Treatment Of MASH With Fibrosis, Compensated Cirrhosis

89bio

27/03/2024 12:50

March 27 (Reuters) - 89Bio Inc  ETNB.O :
    * 89BIO RECEIVES EMA PRIME STATUS FOR PEGOZAFERMIN IN THE
TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
(MASH) WITH FIBROSIS AND COMPENSATED CIRRHOSIS

Source text for Eikon:  ID:nGNX8gd3wF 
Further company coverage:  ETNB.O 

 ((Reuters.Briefs@thomsonreuters.com;))